Rhode Island is currently home to 490 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Providence, Warwick, East Providence and Johnston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
NCT05643534
Recruiting
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and \<18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/12/2024
Locations: Velocity Clinical Research, Providence, East Greenwich, Rhode Island
Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Hasbro Children's, Providence, Rhode Island
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
Youth Partners in Care for Suicide Prevention
NCT05304065
Recruiting
This randomized comparative effectiveness trial will compare two evidence-based approaches to emergency care for youth ages 13-24 who present to the Emergency Department (ED) with suicidal ideation or behavior. Outcomes will be monitored at baseline and at 3, 6 \& 12 month follow-up assessments.
Gender:
ALL
Ages:
Between 13 years and 24 years
Trial Updated:
12/09/2024
Locations: Brown University, Providence, Rhode Island
Conditions: Suicide and Self-harm
Register for Updates
Substance Use Prevention for Youth With Parents in Recovery
NCT05397691
Recruiting
Risk for substance use disorder (SUD) begins early in the life course. Although preventing and decreasing illicit and nonmedical drug use among youth is an urgent public health priority, there are currently few evidence-based prevention strategies feasible for delivery in the primary care setting. The investigators propose a three-year plan to collect critical pilot data to pilot test and optimize a dyadic intervention that aims to increase family resilience, strengthen coping skills, help famil... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/06/2024
Locations: CODAC, Pawtucket, Rhode Island
Conditions: Substance Use Disorders
Register for Updates
Studying the Neuronal Basis of Human Social Cognition
NCT05324579
Recruiting
This proposal aims to study the role that the dorsal prefrontal cortex plays in human social cognition.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Neurosciences
Register for Updates
tDCS to Decrease Opioid Relapse (UH3)
NCT06432465
Recruiting
Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided validation of expected changes in these networks following tDCS stimulation of the DLPFC. In this current phase (II), the investigators will perform a larger randomized clinical trial (RCT) (active vs.... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
12/02/2024
Locations: Butler Hospital, Providence, Rhode Island
Conditions: Opioid Use Disorder
Register for Updates
Optimization of a Behavioral Intervention to Increase Physical Activity in Older Adults Living With HIV
NCT05752500
Recruiting
The goal of this clinical trial is to examine 3 interventions designed to increase physical activity in older adults with HIV. We will examine 3 potential components of an intervention package: physical activity coaching, cognitive behavioral therapy targeted toward common barriers to physical activity such as low motivation or chronic pain, and a Fitbit-based social support intervention. Our primary outcome will be physical activity, defined as steps per day. Results will guide choice of interv... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
12/02/2024
Locations: Lifespan Affiliates, Providence, Rhode Island
Conditions: Hiv, Physical Inactivity, Aging
Register for Updates
Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
NCT05907291
Recruiting
The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of CRN04894 in participants with classic congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency.
Gender:
ALL
Ages:
Between 16 years and 75 years
Trial Updated:
11/22/2024
Locations: Crinetics Study Site, East Providence, Rhode Island
Conditions: Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Register for Updates
A Study of ZN-c3 in Patients With Ovarian Cancer
NCT04516447
Recruiting
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Site 0191, Providence, Rhode Island
Conditions: Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Register for Updates
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964
Recruiting
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. * Were confirmed to have AD at least 6 months ago. * Are not having an effective treatment result from medicines that are applied on skin for AD. * Are considered by their doctors to have moderate to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Clinical Partners, LLC, Johnston, Rhode Island
Conditions: Atopic Dermatitis
Register for Updates
SLC13A5 Deficiency Natural History Study - United States Only
NCT06144957
Recruiting
SLC13A5 deficiency (Citrate Transporter Disorder, EIEE 25) is a rare genetic disorder with neurodevelopmental delays and seizure onset in the first few days of life. This natural history study is designed to address the lack of understanding of disease progression. Additionally it will identify clinical and biomarker endpoints for use in future clinical trials.
Gender:
ALL
Ages:
All
Trial Updated:
11/20/2024
Locations: Brown University, Providence, Rhode Island
Conditions: Citrate Transporter Deficiency, Epilepsy, Rare Diseases, Movement Disorders, Genetic Disorder, SLC13A5 Deficiency, EIEE25, Kohlschutter-Tonz Syndrome (Non-ROGDI), Citrate Transporter Disorder, DEE25
Register for Updates
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371
Recruiting
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Women and Infants Hospital, Providence, Rhode Island
Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Register for Updates